



Collaborative Care in Myelofibrosis

Clinical Brief #1: Unmet Needs in Myelofibrosis: Focus on Anemia and Transfusion Dependency

References

Tweet 2

Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011;29(4):392-397. doi:10.1200/JCO.2010.32.2446

Gerds AT, Bose P, Hobbs GS, et al. treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: current evidence and real-world implications. *Hemasphere*. 2022;6(10):e778. doi:10.1097/HS9.0000000000000778

Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. *J Clin Oncol*. 2018;36(4):310-318. doi:10.1200/JCO.2017.76.4886

Tremblay D, Mesa R. Momelotinib for the treatment of myelofibrosis with anemia. *Future Oncol*. 2022;18(20):2559-2571. doi:10.2217/fon-2022-0276

Additional References

Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. *J Hematol Oncol*. 2022;15(1):7. doi:10.1186/s13045-021-01157-4

Gale RP, Barosi G, Barbui T, et al. What are RBC-transfusion-dependence and -independence? *Leuk Res*. 2011;35(1):8-11. doi:10.1016/j.leukres.2010.07.015

GSK. GSK announces extension of FDA review period for momelotinib. Updated June 16, 2023. Accessed August 30, 2023. <https://www.gsk.com/en-gb/media/press-releases/gsk-announces-extension-of-fda-review-period-for-momelotinib/>

Mesa RA, Su Y, Woolfson A, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. *Health Qual Life Outcomes*. 2019;17(1):61. doi:10.1186/s12955-019-1121-1

MPN Research Foundation. Primary myelofibrosis (MF). Updated 2021. Accessed September 1, 2023. <https://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/>

National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. Updated November 27, 2017. Accessed August 30, 2023. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Myeloproliferative Neoplasms (v2.2023). Updated August 29, 2023. Accessed August 29, 2023. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf

Ning S, Zeller MP. Management of iron deficiency. *Hematology Am Soc Hematol Educ Program*. 2019;2019(1):315-322. doi:10.1182/hematology.2019000034

Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. *Mayo Clin Proc*. 2012;87(1):25-33. doi:10.1016/j.mayocp.2011.11.001

Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. *Lancet*. 2023;401(10373):269-280. doi:10.1016/S0140-6736(22)02036-0

Glossary

CI, confidence interval

DIPSS, dynamic international prognostic scoring system

ESA, erythropoiesis-stimulating agent

Hgb, hemoglobin

HR, hazard ratio

LLN, lower limit of normal

MIPSS, mutation-enhanced international prognostic scoring system

MPN-SD, Modified myeloproliferative neoplasm symptom assessment diary

NA, not applicable

QOL, quality of life

RBC, red blood cell

TD, transfusion dependence

U, unit

w/, with